Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer has successfully warded off three drug manufacturers from placing generics referencing Vyndamax (tafamidis) on the US market, though the…
29 Apr 2026
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with artificial intelligence (AI) biotech, Profluent, to develop recombinases for large-scale…
29 Apr 2026
Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid…
29 Apr 2026
Arcera and Fosun sign MoU for neuroscience innovation
Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding (MoU) for a strategic long-term collaboration in licensing, technology, and neuroscience innovation in the global life sciences industry.…
29 Apr 2026
Rocket to sell PRV for $180m to advance gene therapy pipeline
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance its gene therapy pipeline. The PRV was awarded after the…
28 Apr 2026
Merck KGaA and Remepy join forces to develop combo drug-digital therapies
Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and app-based approaches in rare oncology – marking the first big…
28 Apr 2026
Seaport and Hemab target $180m IPOs as biotech listings accumulate
Seaport Therapeutics and Hemab Therapeutics have both outlined pricings for their respective initial public offerings (IPOs), adding to an already busy month for biotechs making the public jump. Seaport, a…